Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Histol Histopathol ; 20(4): 1115-20, 2005 10.
Artigo em Inglês | MEDLINE | ID: mdl-16136494

RESUMO

Human adrenocortical cells have been shown to express cytokeratins and vimentin. Nestin is an intermediate filament protein that is mainly expressed in the developing nervous system and that has been recently reported in rat adrenal gland as well. Using immunohistochemical and biochemical approaches, the present study demonstrates that nestin is constantly expressed in situ in the cortex of normal human adrenal glands. Nestin expressing cells were prevalently located in the zona reticularis but some positive cells could be spotted in the zona fasciculata as well. Moreover, patches of nestin-positive cells have been constantly detected on sections of cortical adenomas. In contrast, adrenal carcinomas displayed a variable number of nestin-immunoreactive cells that in some cases were virtually absent. Samples of renal clear cell carcinoma metastasis in the adrenals were also examined which did not show nestin-immunoreactivity. We propose that a positive nestin-immunoreaction could be useful in differential diagnosis of clear cell tumors in adrenal glands.


Assuntos
Neoplasias do Córtex Suprarrenal/metabolismo , Glândulas Suprarrenais/metabolismo , Glândulas Suprarrenais/patologia , Proteínas de Filamentos Intermediários/biossíntese , Proteínas do Tecido Nervoso/biossíntese , Adenocarcinoma de Células Claras/metabolismo , Adenocarcinoma de Células Claras/patologia , Neoplasias do Córtex Suprarrenal/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Western Blotting , Estudos de Casos e Controles , Eletroforese em Gel de Poliacrilamida , Feminino , Humanos , Proteínas de Filamentos Intermediários/genética , Masculino , Pessoa de Meia-Idade , Proteínas do Tecido Nervoso/genética , Nestina , Estudos Retrospectivos
2.
J Clin Pathol ; 55(6): 461-6, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12037031

RESUMO

AIM: Several studies have investigated the expression of the cytokeratins (CKs), vimentin, the epithelial growth factor receptor (EGFR), the oestrogen receptor (ER), and the progesterone receptor (PgR), in breast cancer, but no study has directly compared p53 mutations with these phenotypic and differentiation markers in the same case. The present study was designed to provide some of this information. METHODS: The expression of the p53 and bcl-2 proteins was evaluated by immunohistochemistry in relation to phenotypic characteristics and cellular kinetic parameters (mitotic index and apoptotic index) in 37 cases of ductal carcinoma in situ (DCIS) and 27 cases of infiltrating ductal carcinoma (IDC) of the breast. In addition, p53 gene mutation was examined by polymerase chain reaction single strand conformation polymorphism analysis (SSCP). RESULTS: Thirteen cases (eight DCIS and five IDC) showed expression of CK8, CK14, CK18, vimentin, and EGFR, consistent with a stem cell phenotype, whereas 44 cases (27 DCIS and 17 IDC) showed expression of CK8 and CK1, weak or negative expression of CK18, but were negative for vimentin and EGFR, consistent with a luminal cell phenotype. DCIS and IDC cases with a stem cell phenotype were ER/PgR negative and intermediately or poorly differentiated. In contrast, the cases with luminal cell phenotype were ER/PgR positive and well or intermediately differentiated. In addition, intermediately or poorly differentiated cases with a stem cell phenotype showed higher proliferative activity (per cent of MIB-l positive cells) than did intermediately or well differentiated cases with a luminal cell phenotype. Both DCIS and IDC cases with a stem cell phenotype were p53 positive and bcl-2 negative by immunohistochemistry. In IDC, p53 expression was associated with a reduction of both mitotic index and apoptotic index compared with DCIS. Most of the tumours showing a more differentiated phenotype (luminal) were p53 negative and bcl-2 positive. In these cases, cell kinetic parameters increased from DCIS to IDC. These data suggest the existence of subsets of DCIS and IDC that, because of their phenotypic characteristics, could be derived from subpopulations of normal breast cells having different control mechanisms of cell proliferation and neoplastic progression. CONCLUSIONS: These results are compatible with the hypothesis that the phenotype of the cell of origin constrains both tumour phenotype and the choice of genetic events; however, the occurrence of p53 mutants by chance during neoplastic transformation cannot be excluded.


Assuntos
Neoplasias da Mama/genética , Carcinoma Ductal de Mama/genética , Carcinoma Intraductal não Infiltrante/genética , Genes p53 , Mutação , Adulto , Idoso , Idoso de 80 Anos ou mais , Apoptose , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/patologia , Carcinoma Intraductal não Infiltrante/metabolismo , Carcinoma Intraductal não Infiltrante/patologia , Divisão Celular , Receptores ErbB/metabolismo , Feminino , Humanos , Queratinas/metabolismo , Pessoa de Meia-Idade , Índice Mitótico , Proteínas de Neoplasias/metabolismo , Células-Tronco Neoplásicas/patologia , Fenótipo , Reação em Cadeia da Polimerase/métodos , Polimorfismo Conformacional de Fita Simples , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Vimentina/metabolismo
3.
J Submicrosc Cytol Pathol ; 33(3): 245-9, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11846093

RESUMO

Cyclooxygenase-2 (COX-2) is known to be expressed in rat brain and up-regulated by ischemia. The administration of COX inhibitors before as well as soon after the ischemic insult reduces the extension of cerebral damage in rats. Overexpression of COX-2 has also been shown in the ischemic brain of adult human patients, while no information concerning COX-2 expression in neonatal ischemia is available. Intrapartum asphyxia and perinatal brain injury may result in cerebral palsy, mental retardation or epilepsy. COX-2 expression in the brain of neonates delivered after severe birth asphyxia was investigated using immunohistochemistry. Meningeal vessel walls of term and preterm babies widely expressed COX-2 immunoreactivity, as did periventricular large vessels in preterms. A number of brain cells (mature and immature cortical, periventricular and basal ganglia neurons, and oligodendrocytes of the cerebral white matter in brains from term neonates) also expressed COX-2. The present findings suggest that COX-2 may take part in enhancing neonatal brain damage via different mechanisms, such as those involving excitotoxicity and production of reactive oxygen species.


Assuntos
Encéfalo/enzimologia , Hipóxia-Isquemia Encefálica/enzimologia , Isoenzimas/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismo , Doença Aguda , Antígenos CD/metabolismo , Antígenos de Diferenciação Mielomonocítica/metabolismo , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Ciclo-Oxigenase 2 , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Idade Gestacional , Humanos , Hipóxia-Isquemia Encefálica/patologia , Recém-Nascido , Masculino , Proteínas de Membrana , Meninges/irrigação sanguínea , Meninges/enzimologia , Traumatismo por Reperfusão/enzimologia , Traumatismo por Reperfusão/patologia , Regulação para Cima
4.
Prostate ; 39(3): 159-65, 1999 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-10334104

RESUMO

BACKGROUND: Macrophage migration inhibitory factor (MIF) is a lymphokine originally identified for its capacity to inhibit the random migration of macrophages. Recent data have further extended knowledge of the physiological role of this protein, showing that MIF is produced by several human organs and tissues. The present study was intended to evaluate the expression and tissutal localization of MIF in the human prostate. METHODS: Prostate tissues were obtained from patients undergoing surgical adenomectomy for benign prostatic hyperplasia and were analyzed by Western blot, reverse transcriptase-polymerase chain reaction, immunohistochemistry, and immunoelectron microscopy. RESULTS. The presence of both MIF protein and mRNA was demonstrated in the prostate. Immunocytochemical studies localized MIF protein in the secretory luminal epithelial and basal layer cells. CONCLUSIONS: The present study demonstrated that the human prostate is a site of MIF synthesis. Macrophages populate the human prostate and represent an important mechanism of defense of integrity and functionality of the gland. It is speculated that MIF might play a role in preserving prostate physiological activity by maintaining its macrophage population.


Assuntos
Fatores Inibidores da Migração de Macrófagos/análise , Hiperplasia Prostática/metabolismo , Western Blotting , Humanos , Imuno-Histoquímica , Ativação de Macrófagos , Fatores Inibidores da Migração de Macrófagos/fisiologia , Masculino , Hiperplasia Prostática/patologia , RNA Mensageiro/análise , RNA Mensageiro/fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa
5.
Br J Dermatol ; 139(3): 375-9, 1998 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9767280

RESUMO

The histopathological pattern of psoriasis is characterized by dermal inflammatory reaction and hyperproliferation of the epidermis. The mechanism of the epidermal hyperproliferation is not completely understood, but it is probably modulated by the basal lamina (BL), the alterations of which have not been described. We performed the present study to evaluate the expression of the alpha1, alpha2, beta1 and gamma1 laminin chains and collagen IV in the BL of active psoriasis vulgaris before and after cyclosporin treatment administered until the psoriasis was in remission. The results showed that the alpha2 chain is weak and irregular in the lesions, while the alpha1, beta1 and gamma1 chains and collagen IV are normal, with intense and continuous reaction. In the same subjects, this alteration was absent in skin that was clinically unaffected. After treatment with cyclosporin, the altered expression of the alpha2 chain returned to normal in the healing lesions.


Assuntos
Ciclosporina/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Laminina/metabolismo , Psoríase/metabolismo , Adulto , Colágeno/metabolismo , Epiderme/metabolismo , Feminino , Humanos , Técnicas Imunoenzimáticas , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Psoríase/tratamento farmacológico , Pele/metabolismo
6.
J Submicrosc Cytol Pathol ; 30(2): 227-30, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9648286

RESUMO

Components of the blood-brain barrier (BBB) include capillary endothelial cells, the vessel basement membrane (BM) and glial cell interface. While endothelial cell peculiarities are well known and thoroughly studied, BM morphology and functional properties are not. Vessel BM throughout the body is composed of laminin 1, the most common variant of laminin, which is made up of alpha 1, beta 1, and gamma 1 laminin chains, while cerebral vessel BM has been reported to also express the alpha 2 chain. In the present study, we show that the BM of newly formed vessels in brain tumors presents the same immunohistochemical structure as normal brain vessel BM, expressing alpha 1, alpha 2, beta 1, and gamma 1 laminin chains. The function of this particular vessel structure in the central nervous system is not yet completely understood; however, we hypothesize that vessel BM could play a role in impeding the extraneural spreading of brain tumors.


Assuntos
Neoplasias Encefálicas/metabolismo , Encéfalo/patologia , Laminina/biossíntese , Adulto , Idoso , Encéfalo/metabolismo , Neoplasias Encefálicas/patologia , Glioma/metabolismo , Glioma/patologia , Humanos , Técnicas Imunoenzimáticas , Meningioma/metabolismo , Meningioma/patologia , Pessoa de Meia-Idade , Neurilemoma/metabolismo , Neurilemoma/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA